Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside
Figure 3
Antifibrotic effect of TKI: the original target of Imatinib, c-Abl, is involved in several molecular pathways leading to fibrogenesis. Interference of TKI with other molecules involved in fibrotic pathways (PDGFR and Src kinases) are not illustrated due to required simplification.